OHMX.bio

OHMX.bio is a Belgium-based biotechnology startup founded in 2019 that offers innovative OMICS solutions in (epi)genomics, transcriptomics, translatomics, and proteomics. The company's flagship offerings include ribosome profiling and third generation sequencing, aimed at providing a comprehensive R&D platform for biological inquiry.

OHMX.bio's proprietary ribosome profiling service enables a genome-wide assessment of mRNA targeted by translating ribosomes, uncovering vital insights into the translatome. This cutting-edge sequencing-based technology facilitates the quantification of gene-specific translation, the discovery of non-canonical translation events, and the investigation of various mechanisms related to translation regulation, elongation speed, and pausing.

In addition, the company also offers third generation sequencing workflows based on the Oxford Nanopore Technology. This technology allows for amplification-free sequencing of (ultra-)long reads and mapping of their epigenetic features, with applications spanning across clinical, cancer research, environmental and plant research, microbiology, and genome and transcriptome research.

The company recently secured a grant investment on 08 December 2020 from Agentschap Innoveren & Ondernemen, further cementing its position as a prominent player in the biotechnology space.